AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24033725 — intervention group
Group type: COMPARATOR
Intervention: Pressure-driven (PD) device (LifePort; Organ Recovery Systems)
Number of subjects: 50
Study 22204203 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpatellar approach (t-group)
Number of subjects: 50
Study 22204203 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach (p-group)
Number of subjects: 50
Study 18281440 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently Violent Offender program
Number of subjects: 256
Study 18281440 — intervention group
Group type: COMPARATOR
Intervention: Alternate program
Number of subjects: 256
Study 18281440 — intervention group
Group type: COMPARATOR
Intervention: Program noncompletion
Number of subjects: 256
Study 16681477 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg tadalafil taken on demand
Number of subjects: 4262
Study 16681477 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg tadalafil taken three times per week
Number of subjects: 4262
Study 14769687 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention
Number of subjects: 0
Study 14769687 — intervention group
Group type: COMPARATOR
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 14769687 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 11742886 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain meal daily for 16 weeks
Number of subjects: 76
Study 9236562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 225 mg
Number of subjects: 413
Study 9236562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 75 mg
Number of subjects: 413
Study 9236562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 25 mg
Number of subjects: 413
Study 9236562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 7599447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sodium monofluorophosphate and calcium therapy (FC) - 13.2 mg F- (100 mg sodium monofluorophosphate) and 500 mg Ca2+, administered twice a day for 2 years
Number of subjects: 94
Study 7599447 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - 500 mg Ca2+, administered twice a day for 2 years
Number of subjects: 94
Study 2095973 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (0.03 mg/kg iv)
Number of subjects: 12
Study 488880 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g Paromomycin administered on each of the two preoperative days combined with mechanical cleansing of the intestine
Number of subjects: 156
Study 488880 — intervention group
Group type: COMPARATOR
Intervention: Control group (Not-Humatin group)
Number of subjects: 156
Study 488880 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (both intervention and control)
Number of subjects: 156
Study 31151458 — intervention group
Group type: EXPERIMENTAL
Intervention: E-RS:COPD
Number of subjects: 338
Study 28271427 — intervention group
Group type: EXPERIMENTAL
Intervention: WebMOVE (computerized weight management with peer coaching)
Number of subjects: 276
Study 28271427 — intervention group
Group type: COMPARATOR
Intervention: In-person clinician-led weight services
Number of subjects: 276
Study 28271427 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 276
Study 25864906 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Meditation
Number of subjects: 92
Study 25864906 — intervention group
Group type: COMPARATOR
Intervention: Internally Focused Secular Meditation
Number of subjects: 92
Study 25864906 — intervention group
Group type: COMPARATOR
Intervention: Externally Focused Secular Meditation
Number of subjects: 92
Study 25864906 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation
Number of subjects: 92
Study 23709409 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-directed nutrients (BDNs) including fish oil, a high-potency multiple vitamin/mineral supplement, and a brain-enhancement supplement.
Number of subjects: 30
Study 23709409 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-directed nutrients (BDNs)
Number of subjects: 30
Study 23709409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21216328 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane (3 ml via hand-held inhaler)
Number of subjects: 60
Study 21216328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline scented to maintain blindness, 3 ml via hand-held inhaler)
Number of subjects: 60
Study 21216328 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 60
Study 21216328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19638968 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water consumption (2 l) before colonoscopy
Number of subjects: 192
Study 19638968 — intervention group
Group type: COMPARATOR
Intervention: Cold water consumption (2 l) before colonoscopy
Number of subjects: 192
Study 19638968 — intervention group
Group type: COMPARATOR
Intervention: No water consumption before colonoscopy
Number of subjects: 192
Study 17312064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (5, 20, 45 seconds)
Number of subjects: 170
Study 17312064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (10, 25, 50 seconds)
Number of subjects: 170
Study 17312064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (15, 30, 55 seconds)
Number of subjects: 170
Study 17312064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1, Group 2, Group 3
Number of subjects: 170
Study 15527500 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 996
Study 15527500 — intervention group
Group type: EXPERIMENTAL
Intervention: Having pets at home
Number of subjects: 996
Study 15527500 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to nitrogen dioxide (NO2)
Number of subjects: 996
Study 19667564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine with individualized weight-management program
Number of subjects: 0
Study 19667564 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of physical activity
Number of subjects: 0
Study 19667564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 0
Study 19667564 — intervention group
Group type: EXPERIMENTAL
Intervention: New management system
Number of subjects: 0
Study 8638298 — intervention group
Group type: EXPERIMENTAL
Intervention: Total stripping of the long saphenous vein (n = 84)
Number of subjects: 163
Study 8638298 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial stripping of the long saphenous vein (n = 79)
Number of subjects: 163
Study 2057468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (family intervention with advice on diet, smoking, and exercise)
Number of subjects: 1373
Study 2057468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (family intervention)
Number of subjects: 1373
Study 2057468 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1373
Study 2057468 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in intervention group
Number of subjects: 1373
Study 6315789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 16
Study 6315789 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin ultramicrosize
Number of subjects: 16
Study 6315789 — intervention group
Group type: COMPARATOR
Intervention: Topical antifungal cream (after clinical cure)
Number of subjects: 16
Study 29357757 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing integrated with cognitive behavioral therapy (MI‐CBT)
Number of subjects: 10
Study 29357757 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 10
Study 29724385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil added to pirfenidone
Number of subjects: 0
Study 29724385 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to pirfenidone
Number of subjects: 0
Study 26938485 — intervention group
Group type: EXPERIMENTAL
Intervention: Representational disengagement
Number of subjects: 29
Study 26938485 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic disengagement
Number of subjects: 29
Study 24684940 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen for 72 hours (2 or 3 L/min depending on baseline oxygen saturation)
Number of subjects: 0
Study 24684940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen only (2 or 3 L/min depending on baseline oxygen saturation)
Number of subjects: 0
Study 24684940 — intervention group
Group type: COMPARATOR
Intervention: No oxygen (control)
Number of subjects: 0
Study 21744011 — intervention group
Group type: COMPARATOR
Intervention: Creatine (CR; 20 g/day)
Number of subjects: 0
Study 21744011 — intervention group
Group type: COMPARATOR
Intervention: Betaine plus Creatine (BET+CR; 2+20 g/day)
Number of subjects: 0
Study 21744011 — intervention group
Group type: COMPARATOR
Intervention: Betaine (BET; 2 g/day)
Number of subjects: 0
Study 21744011 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PL)
Number of subjects: 0
Study 19195772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 1162
Study 19195772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 1162
Study 19195772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study 17684982 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) in the early postoperative period for preventive purposes
Number of subjects: 62
Study 17684982 — intervention group
Group type: COMPARATOR
Intervention: Moistened oxygen insufflation after transition to spontaneous breathing (Control)
Number of subjects: 62
Study 16167254 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhanced enteral diet
Number of subjects: 72
Study 16167254 — intervention group
Group type: COMPARATOR
Intervention: Regular enteral nutrition (EN)
Number of subjects: 72
Study 11988597 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 122
Study 11988597 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 to 300 mg/d)
Number of subjects: 122
Study 11988597 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 122
Study 11988597 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 122
Study 11988597 — intervention group
Group type: EXPERIMENTAL
Intervention: AF patients on no antithrombotic therapy
Number of subjects: 122
Study 9865219 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423
Study 9865219 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study 7882047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragrance condition (cologne use)
Number of subjects: 60
Study 7882047 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 60
Study 7882047 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 60
Study 7882047 — intervention group
Group type: EXPERIMENTAL
Intervention: Race effect
Number of subjects: 60
Study 7882047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between race and condition
Number of subjects: 60
Study 2486442 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet
Number of subjects: 0
Study 2486442 — intervention group
Group type: COMPARATOR
Intervention: Thiazide-type diuretics
Number of subjects: 0
Study 6102837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 4 x 400 mg
Number of subjects: 10
Study 6102837 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 30998824 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg)
Number of subjects: 596
Study 30998824 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (loading dose 8 mg/kg; maintenance dose 6 mg/kg)
Number of subjects: 596
Study 28383293 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus lumbosacral plexus block with light sedation
Number of subjects: 0
Study 28383293 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus lumbosacral plexus block with deep sedation
Number of subjects: 0
Study 28383293 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without lumbosacral plexus block
Number of subjects: 0
Study 28383293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral plexus block
Number of subjects: 0
Study 25827291 — intervention group
Group type: COMPARATOR
Intervention: Weekly cisplatin 40mg/m2 (Arm C)
Number of subjects: 74
Study 25827291 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 40mg/m2 and gemcitabine 125mg/m2 (Arm CG)
Number of subjects: 74
Study 23800333 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Advocate (PA) intervention for 16 weeks
Number of subjects: 100
Study 23800333 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI) control for 16 weeks
Number of subjects: 100
Study 21540430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal/postpartum lifestyle intervention delivered by telephone
Number of subjects: 197
Study 21540430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal/postpartum lifestyle intervention
Number of subjects: 197
Study 21540430 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 197
Study 19886946 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-coded visual scale images (plain image and graded image)
Number of subjects: 261
Study 19886946 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded image
Number of subjects: 261
Study 19886946 — intervention group
Group type: EXPERIMENTAL
Intervention: Images
Number of subjects: 261
Study 19886946 — intervention group
Group type: COMPARATOR
Intervention: AN lab report
Number of subjects: 261
Study 17901714 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotic prophylaxis
Number of subjects: 397
Study 15157383 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinesterase drugs and steroids treatment
Number of subjects: 77
Study 15157383 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 77
Study 15157383 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 77
Study 15157383 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 77
Study 11232747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 3
Study 11232747 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 3
Study 11232747 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 3
Study 15321241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine bolus (10 mg) and saline infusion
Number of subjects: 30
Study 15321241 — intervention group
Group type: COMPARATOR
Intervention: Saline bolus and saline infusion (Control)
Number of subjects: 30
Study 15321241 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline bolus and two-stage ephedrine infusion (20 mg over 12 min)
Number of subjects: 30
Study 8161862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold start of cardiopulmonary bypass (CPB) with prime at room temperature (approximately 20 degrees C)
Number of subjects: 30
Study 8161862 — intervention group
Group type: COMPARATOR
Intervention: Normothermic start of CPB with prime warmed up to patients' blood temperature
Number of subjects: 30
Study 3118711 — intervention group
Group type: EXPERIMENTAL
Intervention: Defatting with acetone prior to catheter insertion and as part of the every-other-day site care regimen
Number of subjects: 100
Study 31554528 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nutraceutical mixture including DHA, phosphatidylcholine, silymarin, choline, curcumin, d‐α‐tocopherol)
Number of subjects: 113
Study 31554528 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 113
Study 31554528 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 113
Study 29228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using 47 clinical and sociodemographic predictors
Number of subjects: 552
Study 29228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced model with 15 predictors
Number of subjects: 552
Study 29228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MADRS score, impairment of family, social, and work life, timespan between first and last depressive episode, severity, suicidal risk, age, body mass index, number of lifetime depressive episodes, lifetime duration of hospitalization
Number of subjects: 552
Study 29228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified algorithm of 15 predictors
Number of subjects: 552
Study 28501100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg intravenous)
Number of subjects: 96
Study 28501100 — intervention group
Group type: COMPARATOR
Intervention: Direct current synchronized cardioversion (DCC)
Number of subjects: 96
Study 28501100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide conversion subgroup
Number of subjects: 96
Study 28501100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide nonconversion subgroup
Number of subjects: 96
Study 28501100 — intervention group
Group type: COMPARATOR
Intervention: Ibutilide conversion and nonconversion subgroups and DCC group
Number of subjects: 96
Study 28501100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide group
Number of subjects: 96
Study 28501100 — intervention group
Group type: COMPARATOR
Intervention: DCC group
Number of subjects: 96
Study 24081558 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based life skills programmes
Number of subjects: 1057
Study 22366105 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 68
Study 19697298 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessment
Number of subjects: 54
Study 19697298 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 54
Study 19697298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 54
Study 17877952 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant antihormonal therapy (tamoxifen and aromatase inhibitors)
Number of subjects: 0
Study 17877952 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen as primary treatment
Number of subjects: 0
Study 17877952 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 15731395 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT) posture
Number of subjects: 9
Study 15731395 — intervention group
Group type: COMPARATOR
Intervention: Supine posture
Number of subjects: 9
Study 11929056 — intervention group
Group type: EXPERIMENTAL
Intervention: Repellent containing DEET and EBAAP
Number of subjects: 276
Study 11929056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 9796605 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.5 MAC
Number of subjects: 0
Study 9796605 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC
Number of subjects: 0
Study 9796605 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC with Nitrous Oxide (N2O)
Number of subjects: 0
Study 7665538 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/day of clomipramine
Number of subjects: 15
Study 7665538 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day of clomipramine
Number of subjects: 15
Study 7665538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7665538 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (both dosages)
Number of subjects: 15
Study 2719770 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 essential fatty acid (EFA) supplementation
Number of subjects: 0
Study 2719770 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study 795375 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin (2 g daily for 7 days)
Number of subjects: 46
Study 795375 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (2 g daily for 7 days)
Number of subjects: 46
Study 29637282 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral TXA two hours pre-operatively (group A)
Number of subjects: 152
Study 29637282 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral TXA four hours post-operatively (group B)
Number of subjects: 152
Study 29637282 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 boluses of 2 g of oral TXA four, ten, and 16 hours post-operatively (group C)
Number of subjects: 152
Study 29898836 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 655
Study 29898836 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 655
Study 29898836 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional antiplatelet therapy
Number of subjects: 655
Study 27548504 — intervention group
Group type: EXPERIMENTAL
Intervention: Location-based exergame (Fit-Quest)
Number of subjects: 0
Study 24490608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (250 mg twice daily)
Number of subjects: 85
Study 24490608 — intervention group
Group type: COMPARATOR
Intervention: Afatinib (40 mg once daily)
Number of subjects: 85
Study 24490608 — intervention group
Group type: COMPARATOR
Intervention: Combi40 (nintedanib 250 mg twice daily and afatinib 40 mg once daily)
Number of subjects: 85
Study 24490608 — intervention group
Group type: COMPARATOR
Intervention: Combi70 (nintedanib 250 mg twice daily and afatinib 70 mg once daily)
Number of subjects: 85
Study 22933451 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report Beck Depression Inventory (BDI) in GENDEP
Number of subjects: 4852
Study 22933451 — intervention group
Group type: COMPARATOR
Intervention: Clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HRSD) in GENDEP
Number of subjects: 4852
Study 22933451 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report and clinician-rated versions of Quick Inventory of Depressive Symptomatology (QIDS) in STAR*D
Number of subjects: 4852